Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Promise and Progress - Vaccine Clears Out Leukemia Cells
Vaccine Clears Out Leukemia Cells
Date: November 11, 2010
Clinical Cancer Research, January 2010
A leukemia vaccine developed by Kimmel Cancer Center researchers appears to get rid of cancer cells left behind after treatment with the drug Gleevec. While the findings are preliminary, the investigators are cautiously optimistic that the vaccine could improve treatment outcomes and reduce toxic side effects for patients with chronic myeloid leukemia (CML).
Gleevec was introduced about a decade ago as one of the first targeted therapies in cancer and widely celebrated for its ability to specifically destroy malignant cells in patients with CML. While the drug has led to very good responses in many patients, it does not kill all of the cells leaving some patients at risk for relapse, particularly if they stop Gleevec therapy.
"We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," says cancer immunology expert Hyam Levitsky, M.D., who led the team who developed the experimental vaccine.
Levitsky and team say most patients with CML will need to remain on Gleevec therapy for the rest of their lives to remain cancer free, but about 10 to 15 percent of patients cannot tolerate the drug long term. "Ultimately, should this vaccine approach prove to be successful, the ability to get patients off lifelong Gleevec therapy would be a significant advance," says B. Douglas Smith, M.D., who collaborated with Levitsky.
The vaccine is made from CML cells irradiated to halt their cancerous potential and genetically altered to stimulate an immune response against other CML cells. It was given to 19 patients whose cancer was no longer responding to Gleevec therapy. After an average of six years of follow up, 13 patients saw declining numbers of cancer cells, seven of whom had no measurable evidence of disease.
The researchers are now conducting additional studies to confirm that the favorable responses were solely due to the vaccine.
The research was funded by the National Institutes of Health.
Articles in this Issue
Cover Story: Personalized Medicine is Here, The Time is Now
- Personalized Medicine is Here: The Time is Now
- Cover Story Sidebar: Our Cancer Research is Curing Other Diseases Too
- Cover Story Sidebar: A New Paradigm for Cancer Drug Discovery
- Cover Story Sidebar: Personalized Approaches in Pediatric Cancer
- Cover Story Sidebar: The Frankenstein Project
- Cover Story Sidebar: The Serendipitous Discovery of a Cancer Starter
- Cover Story Sidebar: The Mathematics of Curing Cancer
- Immune Cell Commander
- A Personalized Genetic Profile for Brain Cancer
- A New "Twist" in Breast Cancer
- JHU Engineering Student Invents Melanoma Screening Device
- Special Delivery: Biodegradable Particles Transport Drugs to Diseased Tissues and Organs
- Targeting Brain Cancer Stem Cells
- Vaccine Clears Out Leukemia Cells
- Does Low Cholesterol Equal Lower Risk of High-Grade Prostate Cancer?
- A Common Good - The Commonwealth Foundation
- Helping Us Solve The Cancer Puzzle
- The Skip Viragh Center
- Making Waves to Fight Cancer
- Gift Brings Complementary Care to Cancer Patients
- A Major Gift for Kidney Cancer Research
- Giant Food Supports Childhood Cancer Research
- Wawa Cares About Cancer Patients
- Young Lacrosse Players Faced Off Against Childhood Cancer